Chemical Property of Zabofloxacin
Chemical Property:
- PSA：109.05000
- LogP:1.37450
- XLogP3:-0.6
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:10
- Rotatable Bond Count:4
- Exact Mass:401.14993230
- Heavy Atom Count:29
- Complexity:794
- Purity/Quality:
-
97% *data from raw suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CON=C1CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F
- Isomeric SMILES:CO/N=C/1\CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F
- Recent ClinicalTrials:Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin
-
Description
Zabofloxacin
is a quinolone antibiotic originally developed by Dong
Wha Pharmaceuticals and licensed to Pacific Beach Biosciences
in 2007. In March 2015, Korea’s Ministry of Food and Drug
Safety (MFDS) approved zabofloxacin for the treatment of
acute bacterial exacerbation of chronic obstructive pulmonary
disease (ABE-COPD). In 2016, zabofloxacin gained approval
from the USFDA for the treatment of community-acquired
pneumonia. ABE-COPD is caused by respiratory tract and
pulmonary parenchyma that cause chronic pulmonary inflammation
and obstruction in the respiratory tract, which leads to
irreversible damage. In the nonclinical evaluation process,
zabofloxacin showed strong antibiotic activity on respiratory
germs (e.g., Streptococcus pneumonia, S. Haemophilus, S.
moraxella) and was the most potent antibacterial agent against
penicillin-resistant S. pneumoniae (PRSP) in the murine
systemic infection model.
